Vascular Ehlers-Danlos Syndrome – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030

 Vascular Ehlers-Danlos syndrome is an autosomal dominant condition; a child only has to inherit a defect in the COL3A1 gene from one parent to have the disorder. Half of the people with vascular Ehlers-Danlos syndrome inherited the COL3A1 mutation from an affected parent. The other half of people with the condition have a spontaneous disease-causing mutation; they are the first person in their family to have vascular Ehlers-Danlos syndrome. Each child of an affected parent has a 50% chance of inheriting the mutation and developing the disorder. The diagnosis of vascular Ehlers-Danlos syndrome is based on examining and identifying certain features and confirmation by laboratory testing. This testing may include DNA sequence analysis, deletion/duplication analysis, and biochemical (protein-based) testing. Genetic testing detects 98 percent of the changes in the gene for vascular Ehlers-Danlos syndrome; the rest require more specialized tests. Genetic testing is strongly recommended to confirm the vascular Ehlers-Danlos syndrome diagnosis when a person has a combination of any two of the significant features of the condition such as; Arterial rupture, Intestinal rupture, Uterine rupture during pregnancy, Family history of vascular Ehlers-Danlos syndrome.

 

In the United States, the prevalence rate varies between 1 to 2 cases per 200,000 population.

 

The competitive landscape of Vascular Ehlers-Danlos Syndrome includes country-specific approved and pipeline therapies. Any asset/product-specific designation or review and Accelerated Approval are tracked and supplemented with analyst commentary.

KOLs insights of Vascular Ehlers-Danlos Syndrome across 8 MM market from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Vascular Ehlers-Danlos Syndrome Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Read more: Vascular Ehlers-Danlos Syndrome – Market outlook, Epidemiology, Market Forecast, and Competitive Landscape Report – 2020 To 2030

S. No    Asset               Company                                 Stage

1          AR101  Aytu BioPharma            Phase 3